# Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

> **NCT06870435** · NA · RECRUITING · sponsor: **Ming-Yuan Chen** · enrollment: 68649 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)
- Screening
- Epstein Barr Virus

## Interventions

- **BIOLOGICAL:** Blood, nasopharyngeal swab and saliva
- **DIAGNOSTIC_TEST:** EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA
- **DIAGNOSTIC_TEST:** Novel screening biomarkers
- **DIAGNOSTIC_TEST:** Endoscopic examinations with or without biopsy

## Key facts

- **NCT ID:** NCT06870435
- **Lead sponsor:** Ming-Yuan Chen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2026-01-23
- **Final completion:** 2035-12-31
- **Target enrollment:** 68649 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06870435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06870435, "Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06870435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*